Histology
Transitional Cell Carcinoma
CI-CAN-00001613Explore in graph →
253 active trials5 approved drugs22 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001613Explore in graph →
Clinical trials
734 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (119)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02986867 | SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma | completed | N/A | 27 | University of Texas Southwestern Medical CenterOTHER | 1 | Jan 10, 2019 | clinicaltrials |
| NCT03794102 | Water Versus Saline as Irrigation Fluid for Ureteroscopy | completed | N/A | 150 | Emory UniversityOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT03419130 |
| Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer |
| withdrawn |
| Phase 2 |
| 0 |
| University of California, San FranciscoOTHER |
| 1 |
| Dec 7, 2018 |
| clinicaltrials |
| NCT01668459 | Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel(CabB1) | completed | Phase 2 / Phase 3 | 20 | Dr Anjali ZarkarOTHER | 1 | Dec 4, 2018 | clinicaltrials |
| NCT03745911 | Paclitaxel and TAK-228 in Urothelial Carcinoma | unknown | Phase 2 | 52 | Associació per a la Recerca Oncologica, SpainOTHER | 1 | Nov 19, 2018 | clinicaltrials |
| NCT02334527 | Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy | terminated | Phase 2 | 12 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 16, 2018 | clinicaltrials |
| NCT03208712 | Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy | terminated | Early Phase 1 | 1 | University of Michigan Rogel Cancer CenterOTHER | 1 | Oct 24, 2018 | clinicaltrials |
| NCT03676946 | A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial Carcinoma | unknown | Phase 1 / Phase 2 | 15 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Sep 26, 2018 | clinicaltrials |
| NCT00880334 | Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC | completed | Phase 2 | 149 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT03577132 | The Efficacy of Neoadjuvant Atezolizumab Treatment in Patients With Advanced Urothelial Bladder Cancer | unknown | N/A | 20 | Seoul National University HospitalOTHER | 0 | Jul 31, 2018 | clinicaltrials |
| NCT03013894 | Confocal Laser Endomicroscopy in the Lower Urinary Tract | completed | — | 73 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jun 6, 2018 | clinicaltrials |
| NCT03013920 | CLE Characteristics of Upper Urinary Tract Urothelial Carcinoma | completed | — | 150 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jun 6, 2018 | clinicaltrials |
| NCT00899093 | YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy | terminated | — | 2,500 | Gynecologic Oncology GroupNETWORK | 1 | May 22, 2018 | clinicaltrials |
| NCT01440998 | Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Apr 5, 2018 | clinicaltrials |
| NCT01234519 | A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy | terminated | Phase 1 / Phase 2 | 12 | AEterna ZentarisINDUSTRY | 1 | Mar 15, 2018 | clinicaltrials |
| NCT01642082 | Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 28 | Gynecologic Oncology GroupNETWORK | 1 | Mar 13, 2018 | clinicaltrials |
| NCT03076372 | A Study Evaluating MM-310 in Patients With Solid Tumors | unknown | Phase 1 | 34 | Merrimack PharmaceuticalsINDUSTRY | 1 | Feb 27, 2018 | clinicaltrials |
| NCT00719303 | Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | unknown | Phase 3 | 1,070 | Gynecologic Oncology GroupNETWORK | 1 | Feb 19, 2018 | clinicaltrials |
| NCT02014337 | Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors | completed | Phase 1 | 37 | Corcept TherapeuticsINDUSTRY | 1 | Jan 17, 2018 | clinicaltrials |
| NCT02514408 | Circulating Tumor Cells in Operative Blood in Patients With Bladder Cancer | withdrawn | — | 0 | University of Southern CaliforniaOTHER | 0 | Jan 2, 2018 | clinicaltrials |
| NCT03238664 | Robot-Assisted Laparoscopic High-Intensity Focused Ultrasound and Radical Cystectomy for Thermal Ablation of Muscle Invasive Cells in Patients With Bladder Tumors | withdrawn | N/A | 0 | University of Southern CaliforniaOTHER | 0 | Jan 2, 2018 | clinicaltrials |
| NCT03209206 | The Effectiveness and Safety of Intravesical Docetaxel Instillation for Prevent Bladder Recurrence | unknown | Phase 2 | 84 | Seoul National University HospitalOTHER | 1 | Dec 22, 2017 | clinicaltrials |
| NCT00888173 | Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 45 | Gynecologic Oncology GroupNETWORK | 1 | Dec 6, 2017 | clinicaltrials |
| NCT02944357 | Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery | withdrawn | N/A | 0 | Mayo ClinicOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT01225887 | Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 37 | Gynecologic Oncology GroupNETWORK | 1 | Oct 9, 2017 | clinicaltrials |
| NCT01310803 | Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder | terminated | Phase 3 | 1 | Endo USA Inc., a Keenova Therapeutics CompanyINDUSTRY | 1 | Oct 5, 2017 | clinicaltrials |
| NCT03296306 | Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma(FOCUS) | unknown | Phase 3 | 330 | Asan Medical CenterOTHER | 1 | Sep 28, 2017 | clinicaltrials |
| NCT03280459 | Evaluation of Robot-assisted Intracorporeal Urinary Reconstruction(iRARC-KSW) | unknown | — | 200 | Kantonsspital Winterthur KSWOTHER | 1 | Sep 12, 2017 | clinicaltrials |
| NCT02236195 | Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes | completed | Phase 2 | 17 | Mirati Therapeutics Inc.INDUSTRY | 1 | Sep 1, 2017 | clinicaltrials |
| NCT01200992 | Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer(EMBARC-RF) | terminated | Phase 3 | 84 | Bioniche Life Sciences Inc.INDUSTRY | 6 | Aug 24, 2017 | clinicaltrials |
| NCT01042795 | Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy | terminated | Phase 2 | 7 | University of MichiganOTHER | 1 | Jun 28, 2017 | clinicaltrials |
| NCT03193788 | Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy(PREMIER) | unknown | Phase 3 | 74 | Asan Medical CenterOTHER | 1 | Jun 21, 2017 | clinicaltrials |
| NCT01353222 | DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma | terminated | Phase 2 | 142 | DendreonINDUSTRY | 1 | May 25, 2017 | clinicaltrials |
| NCT03138824 | Storz Professional Image Enhancement System Versus White Light Imaging Assisted TURBT for Treatment of NMIBC | unknown | N/A | 100 | Mansoura UniversityOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT02160600 | Dual Energy CT vs Standard Triple Phase CT-A Randomised Control Trial | completed | N/A | 124 | All India Institute of Medical SciencesOTHER | 1 | Apr 27, 2017 | clinicaltrials |
| NCT01328574 | TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Jan 13, 2017 | clinicaltrials |
| NCT00565227 | Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies. | terminated | Phase 1 | 12 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 2, 2016 | clinicaltrials |
| NCT02589717 | An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy | approved for marketing | — | — | Genentech, Inc.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT00683059 | Single Agent Abraxane as Second Line Therapy in Bladder Cancer | completed | Phase 2 | 48 | Sunnybrook Health Sciences CentreOTHER | 1 | Oct 17, 2016 | clinicaltrials |
| NCT01522820 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT00362713 | Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection | completed | Phase 1 | 12 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 30, 2016 | clinicaltrials |
| NCT02471547 | Intravesically Heated Thermo-chemotherapy With Mitomycin-C Prior to TURBT | unknown | N/A | 300 | Sheba Medical CenterOTHER_GOV | 1 | Apr 28, 2016 | clinicaltrials |
| NCT01606345 | Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma | completed | Phase 1 | 4 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 22, 2016 | clinicaltrials |
| NCT02718742 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer | withdrawn | Phase 2 | 0 | Mayo ClinicOTHER | 1 | Apr 18, 2016 | clinicaltrials |
| NCT02479178 | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck(iNSITE2) | terminated | Phase 2 | 73 | BIND TherapeuticsINDUSTRY | 2 | Apr 14, 2016 | clinicaltrials |
| NCT00588666 | Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 22, 2016 | clinicaltrials |
| NCT00612326 | Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging | completed | — | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 18, 2015 | clinicaltrials |
| NCT01599013 | JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin(JASINT1) | completed | Phase 2 | 69 | Pierre Fabre MedicamentINDUSTRY | 1 | Dec 8, 2015 | clinicaltrials |
| NCT00389155 | First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy | completed | Phase 2 / Phase 3 | 34 | Bristol-Myers SquibbINDUSTRY | 16 | Dec 7, 2015 | clinicaltrials |
| NCT00633789 | Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types | completed | Phase 2 | 597 | Bristol-Myers SquibbINDUSTRY | 9 | Oct 9, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Jan 10, 2019source: clinicaltrials